Averin Capital

General contacts
Investor type

VC

Founded

2024

AUM

-

Location

New York, New York, United States

Investment Ticket

-

Investment Stage

Series B Series A Seed Pre-seed Late Stage (Series C+)

Region of investment

North America Europe Asia
Investor profile last updated: 18 October, 2026

Profile

Averin Capital is a New York-based venture capital firm, founded in 2024, that backs and builds early-stage companies transforming human health through AI and breakthrough technologies. Its team includes physicians, scientists, founders, healthcare executives and investors, who work with founders on operating decisions, anticipate challenges and make introductions to people who can help build the business.

The firm invests across five areas: foundational science (tools for research, diagnostics and drug development), physical AI (robotics, sensors and intelligent medical devices), care delivery, healthcare infrastructure (clinical trials, manufacturing, data exchange and payments) and human performance. Its typical initial investment is $500,000 to $10 million, at pre-seed, seed, Series A and later stages, across the US, Europe and Asia. Averin Capital sometimes leads rounds.

Portfolio companies include Biolinq, Pine Park Health, Hologen AI, CandidPro, Freenome and Mendaera.

Industry

Biotechnology New materials HealthTech AI Robotics Healthcare Services Medical Devices Technology Life Sciences Deeptech

Contacts

Name
Title
Email
Social Networks
avatar
David Berry, MD PhD Managing Partner
Managing Partner
d•••@•••
LinkedIn
avatar
Eric Berry Managing Partner
Managing Partner
e•••@•••
LinkedIn
Upgrade to see contacts
avatar
UW9T01yxDhOZP7e8 UW9T01yxDhOZP7e8
UW9T01yxDhOZP7e8
[email protected]
linkedin twitter
avatar
UW9T01yxDhOZP7e8 UW9T01yxDhOZP7e8
UW9T01yxDhOZP7e8
[email protected]
linkedin twitter
avatar
UW9T01yxDhOZP7e8 UW9T01yxDhOZP7e8
UW9T01yxDhOZP7e8
[email protected]
linkedin twitter
Investment-team contacts for Averin Capital — including verified work emails and LinkedIn profiles — are available to Private Equity List subscribers.
Instant access on the web. Plans from $129/month — see pricing.
Contacts sourced from the firm's website and LinkedIn, re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

FAQs about Averin Capital

Averin Capital is a venture capital firm. It backs companies at Series B, Series A, Seed, Pre-seed and Late Stage (Series C+).
Averin Capital is located in New York, New York, United States.
Averin Capital was founded in 2024.
Averin Capital invests in companies and startups in Biotechnology, New materials, HealthTech, AI, Robotics, Healthcare Services, Medical Devices, Technology, Life Sciences, Deeptech.
Averin Capital invests in companies and startups in North America, Europe, Asia.
Averin Capital invests in companies and startups at Series B, Series A, Seed, Pre-seed, Late Stage (Series C+).
Averin Capital can be reached through its website averincapital.com, its LinkedIn page and its X account. Cold-mailing a general inbox rarely reaches a partner, so Private Equity List also lists the investment-team contacts for Averin Capital — names, roles, verified work emails and LinkedIn profiles — available on a Pro plan from $129/month (see pricing). Contacts are sourced from the firm's website and LinkedIn and re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.
Yes. Every field on this page — profile, funds, investment criteria, portfolio and investment-team contacts — is available programmatically through the Private Equity List REST API and MCP server, so AI assistants such as Claude and ChatGPT can query Averin Capital directly instead of scraping this page. One subscription covers both the web app and machine access — see API & MCP.
Private Equity List re-verifies investor profiles on a rolling cycle, pulling from the firm's own website and LinkedIn rather than a one-off import. This profile was last updated on 18 October, 2026. Something out of date here? Report it — we re-run that firm within 48h and get back to you.